Protein binding domains stabilizing functional conformational states of GPCRs and uses thereof
US-9689872-B2 · Jun 27, 2017 · US
US10054598B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10054598-B2 |
| Application number | US-201715819500-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2017 |
| Priority date | Jul 16, 2010 |
| Publication date | Aug 21, 2018 |
| Grant date | Aug 21, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.
Opening claim text (preview).
What is claimed is: 1. A polypeptide comprising an amino acid sequence that consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementary determining regions (CDR1 to CDR3, respectively) according to the formula: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein CDR1 is the amino acid sequence of SEQ ID NO:31 or an amino acid sequence that has at least 80% identity with SEQ ID NO:31, wherein CDR2 is the amino acid sequence of SEQ ID NO:44 or an amino acid sequence that has at least 80% identity with SEQ ID NO:44 and wherein CDR3 is the amino acid sequence of SEQ ID NO:59 or an amino acid sequence that has at least 80% identity with SEQ ID NO:59, wherein said polypeptide has binding activity for human β 2 adrenergic receptor. 2. The polypeptide according to claim 1 comprising an amino acid sequence that has at least 80% identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO: 10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO: 15, SEQ ID NO:16 and SEQ ID NO:17. 3. A composition comprising the polypeptide according to claim 1 . 4. A composition comprising the polypeptide according to claim 2 .
Related publications grouped by family.
Answers are generated from the same data shown on this page.